Oertli launches next generation microincision instruments

Article

Oertli has launched new instruments to be used in microincision surgery for the anterior and the posterior segments.

Oertli has launched new instruments to be used in microincision surgery for the anterior and the posterior segments.

For the anterior segment, Oertli has introduced the CO-MICS 2 tip for 1.6 mm phaco, which is fully compatible with the existing OS3, SwissTech and CataRhex platforms. This product builds on Oertli's portfolio of instruments that enable surgeons to perform coaxial microincision cataract surgery (CO-MICS), now, through a groundbreaking microincision of 1.6 mm.

In the posterior segment, the company has launched a new 23G autoseal PMS pars plana microincision surgery system set with self-sealing trocars, which is available as a complete vitrectomy pack for Oertli's OS3 NovitreX3000 platform or individually, as a sterile disposable set of 10 pieces.

The CO-MICS 2 set (left) combines phaco tip and irrigation sleeve to provide enhanced chamber stability during microcoaxial phaco. It provides the same performance and ultrasound times as standard phaco, with enhanced holdability force, stability and fluidic properties but reduced lateral forces, and no turbulence.

The 23G autoseal PMS pars plana microincision surgery system (below) for transconjunctival vitrectomy without the need for sutures has an integrated sealing valve, which does not necessitate sealing during surgery and enables easier and faster plug-sealing with no loss of pressure following vitrectomy.

Both the CO-MICS 2 and the 23G PMS are available now and can be seen by visiting Oertli at booth number 1560, Hall 15, during this year's ESCRS congress in September, Berlin, Germany.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
Related Content
© 2025 MJH Life Sciences

All rights reserved.